欢迎访问浙江中西医结合杂志   今天是   加入收藏   |   设为首页
王剑荣,郑永科,余伶俐,钟益刚.高血压及不同降压药物对新型冠状病毒肺炎患者血生化、炎症因子、凝血的影响[J].浙江中西医结合杂志,2020,30(10):
高血压及不同降压药物对新型冠状病毒肺炎患者血生化、炎症因子、凝血的影响
Effect of hypertension and different antihypertensive drugs on biochemical indicators, inflammatory, coagulation of the patients with new coronavirus pneumonia
投稿时间:2020-07-28  修订日期:2020-08-28
DOI:
中文关键词:  COVID-19  高血压  血管紧张素转换酶抑制剂  血管紧张素受体拮抗剂
英文关键词:2019-nCov  hypertension  angiotensin converting enzyme inhibitors  angiotensin receptor antagonists.
基金项目:
作者单位E-mail
王剑荣 杭州市第一人民医院杭州市援鄂医疗队 skywalkerhz@hotmail.com 
郑永科 杭州市第一人民医院杭州市援鄂医疗队  
余伶俐 华中科技大学同济医学院附属同济医院  
钟益刚 杭州市第一人民医院杭州市援鄂医疗队  
摘要点击次数: 87
全文下载次数: 0
中文摘要:
      [摘要] 目的:探索高血压合并新型冠状病毒肺炎(COVID-19 )患者的生化、炎症因子、凝血功能的情况及不同降压药物对这些指标的影响。 方法:回顾性分析 2020年2月9日至2020年3月30日入武汉同济医院光谷院区的 57例 COVID-19肺炎患者,根据既往有无高血压分为高血压组(n=27)和无高血压组(n=30),再根据既往是否使用血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体拮抗剂(ARB)治疗分为ACEI/ARB组(n=14)和其他降压药组(n=13),分组后比较各组入院时的全血细胞计数、C反应蛋白(CRP)、心肌损伤标志物、凝血功能、肝肾功能、B型利钠肽(BNP)、炎症指标等。 结果:与无高血压组比较,高血压组患者年龄[64.0(54.0,70.0)岁比48.5(38.75,64.0)岁,P=0.001]较大,白细胞计数[6.16(5.46,7.81) 比5.04(4.30,6.12),P=0.004]较高,中性粒细胞计数[4.15(2.68,5.81)比 2.66(2.11,4.00),P=0.004]较高,CK-MB [0.8(0.5,1.1)比0.5(0.38,0.60),P=0.004]较高。TNI [4.9(2.6,9.8)比2.0(1.9,3.9),P=0.001]较高;ARB/ACEI组与其他降压药组相比较,生化、炎症因子、凝血功能均无明显统计学差异。 结论:COVID-19合并高血压病的患者炎症指标更高,心肌损伤更明显,可能与更差的预后有关。ACEI/ARB不影响 COVID-19 合并高血压患者的炎症因子和凝血功能。
英文摘要:
      [Abstract] Objective :To explore the biochemical indicators, inflammatory, coagulation of patients with hypertension complicated with new coronavirus pneumonia (COVID-19) ,and the influence of different antihypertensive drugs on these indicators. Methods: A retrospective analysis of 57 patients with COVID-19 pneumonia who were admitted to the Guanggu District of Wuhan Tongji Hospital from February 9, 2020, to March 30, 2020, these patients were divided into the hypertension group (n=27) And non-hypertensive group (n=30)according to previous hypertension, afterward, they were divided into ACEI/ARB group (n=14) and Other antihypertensive drug groups (n=13), we compared the Blood routine, C-reactive protein (CRP), myocardial injury markers, coagulation, liver and kidney markers, B-type natriuretic peptide (BNP) in each group upon admission, Inflammation indicators. Results :Compared to the non-hypertensive group, the age of patients in the hypertensive group [64.0 (54.0, 70.0) years VS 48.5 (38.75, 64.0) years, P=0.001]was older, and the white blood cell count [6.16 (5.46, 7.81)] VS 5.04 (4.30) , 6.12), P=0.004] was higher, neutrophil count [4.15 (2.68, 5.81) VS2.66 (2.11, 4.00), P=0.004] was higher, CK-MB [0.8 (0.5, 1.1) VS 0.5 (0.38, 0.60), P=0.004] was higher. TNI [4.9 (2.6, 9.8) VS 2.0 (1.9, 3.9), P=0.001]was higher.; compared with other antihypertensive drug groups, the ARB/ACEI group has no significant differences in biochemistry, inflammatory, and coagulation. Conclusion :Patients with COVID-19 and hypertension have higher inflammatory indicators and elevated myocardial markers, which may be related to a worsed prognosis. ACEI/ARB does not affect the inflammatory and coagulation of patients with hypertension in COVID-19.
查看全文  查看/发表评论  下载PDF阅读器
关闭